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Abstract
Endovascular Aneurysm Repair (EVAR) for the treatment of aortic abdominal aneurism has been 
shown to improve short-term survival and quality of life as compared to Open Repair (OR), while 
reducing the rate of serious complications and allowing for the treatment of more patients. 
Objectives: To examine the cost-effectiveness of EVAR compared to OR in the treatment of 
aortic abdominal aneurism in the Portuguese context using a model previously developed in 
the UK.
Methodology: We adapted an international economic evaluation model to the Portuguese 
situation, assuming that the health benefits of EVAR observed in clinical trials would also 
apply to Portuguese patients. We carried out an expert panel survey to calculate the resource 
use associated with the intervention and its short and long-term consequences, valued with 
Portuguese prices. 
Results: The major cost difference in the primary intervention (difference of 3,064 € in favor 
of OR) is related to the cost of the endograft/graft. No major differences are observed in the 
total cost of complications and re-interventions between the two procedures. EVAR represents 
a cost of 16,709 € over lifetime compared to 12,130 € for OR. Using data from the literature 
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Introduction
Abdominal aortic aneurysm (AAA) is a serious health condition 
with a high mortality risk in developed countries. For example, 
in Canada AAA is the 10th leading cause of death in men 65 years 
or older.1 The risk of AAA rupture is low, but it increases with 
the increasing diameter of the aneurysm. In case of AAA 
rupture mortality is very high, e.g., it has been estimated to 
vary between 85% to 95% in the Netherlands.2-4 As aneurysms 
commonly remain asymptomatic until they rupture, a close 
surveillance of the diameter is needed. Elective abdominal 
aneurysm repair is usually indicated for aneurysms with a 
diameter greater than 5.5 cm.1,5 Mortality in case of elective 
aneurysm repair is by contrast lower, below 5%.6-9
Over the past 15 or 20 years the treatment of AAA has 
changed considerably. Traditionally AAA has been treated 
through conventional Open Surgical Repair (OR), which is a 
major but generally successful procedure, with established 
and definite mortality risk and complication rate, although 
its long-term re-intervention rates are often underestimated. 
However, the Endovascular Aneurysm Repair (EVAR) has 
increased over the recent years as a substitute for OR. It is 
a minimally invasive alternative to OR, first performed by 
Volodos in Kharkov, Ukraine and published in 1986.5 Since 
EVAR is less invasive compared to conventional OR, it 
we show that EVAR allows for 0.17 additional undiscounted years of life and 0.091 additional 
undiscounted quality-adjusted life years. The incremental cost-effectiveness ratio (ICER) of 
EVAR is of 65,605 €/QALY. 
Conclusion: Endovascular repair of aortic abdominal aneurysm represents an effective 
alternative and has been used increasingly in Portugal and elsewhere. Our study shows that its 
cost-effectiveness is currently above the commonly accepted threshold in Portugal, but that the 
economic value of EVAR would greatly improve if beneÀ ts were conÀ rmed in the long run after 
the intervention. Under these circumstances, EVAR would become an economically valuable 
intervention that could be adopted on a large scale in Portugal. 
© 2014 Sociedade Portuguesa de Angiologia e Cirurgia Vascular. Published by Elsevier España, S.L. 
All rights reserved.
Custo-efetividade no tratamento do aneurisma da aorta abdominal: uma abordagem 
no contexto Português
Resumo
O tratamento endovascular (EVAR) do aneurisma da aorta abdominal tem sido apontado, nos 
últimos anos, como uma alternativa bastante atrativa à cirurgia convencional. Não obstante tais 
benefícios clínicos e percepcionados pelos doentes, os estudos de avaliação económica parecem 
não ser tão consistentes, o que requer algumas considerações aquando da utilização desta 
opção terapêutica em larga escala.
Objetivos: Avaliar, no contexto Português, o custo-efetividade do EVAR no tratamento do 
aneurisma da aorta abdominal comparado com o tratamento por cirurgia convencional, usando 
um modelo desenvolvido previamente no Reino Unido.
Metodologia: Os benefícios foram baseados em estudos clínicos internacionais, assumindo que 
tais resultados podem ser aplicados ao contexto Português. Constituiu-se um painel de peritos 
para apurar a utilização de recursos associados à intervenção bem como as consequências a 
curto e médio prazo (valorizados com preços de Portugal). 
Resultados: A diferença de custos na intervenção primária entre o EVAR e o tratamento por 
cirurgia convencional, deveu-se ao preço da endoprótese. Não se veriÀ caram diferenças, entre 
ambos os procedimentos, no que respeita ao custo total associado às complicações e 
reintervenções. O rácio custo-efetividade incremental (ICER) do EVAR foi de 65,605€/QALY.
Conclusões: O tratamento endovascular do aneurisma da aorta abdominal apresenta resultados 
que parecem comprovar uma elevada efetividade tendo sido utilizada, nos últimos anos, de 
forma crescente um pouco por todo o mundo. Apesar dos resultados custo-efetividade, aqui 
apurados, estarem acima do que que é considerado limiar de aceitação em Portugal, o valor 
económico do EVAR melhoraria se se conÀ rmassem os benefícios a longo prazo que, alguns dos 
estudos recentes, parecem apontar. Nessas circunstâncias, o tratamento endovascular 
tornar-se-ia uma intervenção economicamente interessante que, aliada aos bons resultados ao 
nível da efetividade e da qualidade de vida dos doentes, poderia ser indicada para um maior 
número de situações clínicas.
© 2014 Sociedade Portuguesa de Angiologia e Cirurgia Vascular. Publicado por Elsevier España, S.L. 
Todos os direitos reservados.
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intuitively leads to fewer postoperative complications, 
faster recovery, and shorter hospital stays.6,10 This advantage 
clearly suggests that this is the preferred procedure for 
high-risk patients.11-13
While the outcomes and durability of OR are well 
established, some concerns remain regarding the durability 
and long-term results of EVAR, namely its increased need 
for re-interventions and benefits on long-term survival.10 On 
the one hand, trials indicate that 30-days all-cause mortality 
risk increases by 4.61 (Hazard Ratio HR) (p<0.001) with OR 
as compared to EVAR. Also, long-term all-cause mortality 
risk increases by 1.24 (HR), and long-term AAA mortality risk 
by 4.37 (HR) after OR as compared to EVAR, when adjusted 
for different variables.14 However, there is a concern for 
complications and re-intervention rates, and the literature 
shows widely varying results. Also, EVAR is considered to 
be an expensive procedure,2,5,7,8,11 with a need for close 
surveillance of endografts over many years, and possible 
conversion to OR.15 The cost comparison between EVAR 
and OR is, however, also controversial. Indeed, Mani et 
al.16 observed similar clinical and hospital-related costs for 
both procedures, and Stroupe et al.17 lower costs for EVAR; 
conversely, Epstein et al.18 estimated that lifetime costs 
were higher after EVAR by 3,758£/4,491€ (15,823 £/18,909 € 
for EVAR versus 12,065 £/14,418 € for OR). 
Despite these possible limitations, EVAR has increasingly 
replaced OR among older patients not suited for the 
open-surgery procedure, due to its greater short-term 
efficacy. For example, in the US the number of elective AAA 
treated with OR fell from 17,784 to 8,451 between 2001 and 
2006, while the number of patients treated with EVAR 
increased from 11,171 to 21,725 in the same period.19 Although 
EVAR is certainly promising in clinical terms, it potentially 
imposes an additional financial burden on the National 
Health Service (NHS). Given the adverse economic context 
and the deficit crisis of the Portuguese state, it is necessary 
now more than ever to carefully assess these potential 
additional costs and evaluate whether they are worth it. To 
do so, we perform an economic evaluation measuring costs 
and consequences of EVAR as compared to OR for Portugal, 
from the National Health Service perspective. 
Methodology
We used an economic evaluation model developed by 
Abacus International in 2007 and used (adapted for ruptured 
cases) by Hayes et al.20 This model, developed in Microsoft 
Excel, includes a decision tree to capture 30-day costs and 
outcomes, and a Markov model to evaluate long-term costs 
and health outcomes, from 30 days post-surgery to death. 
The model assumes two cohorts of 1,000 patients with an 
average age of 70 years old and treated with EVAR and OR, 
respectively. Patients are followed over a 30-year period. All 
details of the model can be found in Hayes et al.20 Table 1 
summarizes the main health outcomes (we used health 
consequences from Hayes et al. based on clinical trials) used 
as inputs for the model and their source. We adopted an 
actualization rate of 5%, following the Portuguese guidelines 
for economic evaluation.21
Table 1 Health outcomes used in the model developed by Abacus International in 2007 and later used (adapted for ruptured 
cases) by Hayes et al., 2010.
EVAR OR
 Percent Reference Percent Reference
Mortality
 30-days mortality 1.59% Brown et al 200731 4.20% Brown et al 200731
 Long term AAA-related mortality 
  (up to 4 years post op)
0.04% Extrapolated from Brown 
 et al 2007,31 monthly rate
0.03% Extrapolated from Brown 
 et al. 2007, monthly rate
 Long term all-cause mortality 
  (up to 4 years post op)
0.48% Extrapolated from Brown 
 et al. 2007,31 monthly rate
0.46% Extrapolated from Brown 
 et al. 2007,30 monthly rate
Reinterventions – 30 days 1.72% EVAR trial participants 200515 1.03% EVAR trial participants 200515
Reinterventions – 2-6 months 1.72% EVAR trial participants 200515 1.03% EVAR trial participants 200515
Reinterventions – Long term 0.27% EVAR trial participants 200515 — Not mentioned
Complications – 30 days
 Cardiac (MI) 1.92% EUROSTARa; Hua et al 200512 
 adjusted values
4.55% Meta-analysis
 Renal failure 0.83% EUROSTAR; Hua et al 200512 
 adjusted values
1.42% Meta-analysis
 Pulmonary 0.00% Not mentioned 0.00%
 Neurologic (stroke) 0.60% EUROSTAR 1.70% Meta-analysis
Complications – 1-18 months
 Cardiac (MI) 0.30% Assumption, monthly rate 0.09% Assumption, monthly rate
 Renal failure 0.00% Not mentioned 0.00% Not mentioned
 Pulmonary 0.00% Not mentioned 0.00% Not mentioned
 Neurologic (stroke) 0.19% Assumption, monthly rate 0.13% Assumption, monthly rate
a International registration database.
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Costs
For the resource used we considered all direct costs for 
Portugal associated with treatment of AAA by EVAR and 
OR. We included all costs related to surgical procedures and 
in-patient stay, including drugs, diagnostic exams, and bed 
days; all costs associated with follow-up, re-interventions, 
and complications over an 18-month time horizon. Regarding 
the follow-up period, we considered only in-patient care, 
since ambulatory care costs are negligible compared to 
those of hospitalization. Nevertheless, we included all drug 
costs prescribed at the hospital, even if the patient had to 
acquire them at a community pharmacy.
To measure resources we carried out an expert panel 
analysis using the modified Delphi technique with two 
rounds. The questionnaire (based on the Hayes et al. model, 
2010)20 included questions related to resource use items 
mentioned above, and also some questions about clinical 
outcomes (re-interventions, complications, and mortality) 
in order to validate for Portugal outcomes obtained in the 
international literature and to obtain some information 
about health outcomes. The use of a modified Delphi method 
was necessary as no observational data were available for 
Portugal. The first round consisted of a meeting with all 
experts in which the study and questionnaire were presented, 
which was then filled in by each expert independently. The 
research team then compiled the answers and performed a 
statistical analysis, whose anonymous results were sent to 
experts for review (second round). 
The choice of experts was performed as follows. We 
accessed the database of all in-patient stays at NHS 
hospitals during the year 2010.21,22 Based on this information, 
we chose the seven hospitals with the greatest number of 
EVAR and OR interventions for the period, in order to have 
an uneven number of experts and sufficient geographic and 
practice representation. One of these hospitals was unable 
to participate in the study due to logistic constraints, so 
we selected the hospital with the next highest number of 
EVAR and OR interventions over the period. These hospitals 
represent up to 88.8% (168) of the total 189 EVAR performed 
during the year 2010 at NHS hospitals in Portugal, and 74.4% 
(119) of the 160 OR interventions. One response was not 
returned in time despite several reminders, and we were 
thus able to include only six hospitals, which represented 
in 2010 73.5% and 70.0% of EVAR and OR procedures, 
respectively.
In order to value resource use associated with treatment 
of AAA by EVAR and OR, we used several Portuguese 
national sources. We used the “Catalogue of Health Public 
Procurement” (Catálogo de Aprovisionamento Público da 
Saúde) to assign unit costs to drugs.23 Official tariffs from 
the Ministry of Health were used to obtain unit costs of blood 
products,24 diagnostic tests, and in-patient stays except 
for primary intervention.25 We used the average official 
salary tables for civil servants to assign costs for human 
resources.26 Finally, we used 2009 accounting data from 
Portuguese NHS hospitals to assign unit costs to medical 
visits and operating rooms.27 To assign the unit cost for 
the contrast agent and the graft used in OR, we contacted 
individually the manufacturers with the highest market 
shares in Portugal and used the average of the prices we 
received. Finally, regarding the unit cost of the endograft 
used in EVAR, we considered the average price of the 
Medtronic endograft for Portugal in 2012, following the 
Hayes et al. study.
Total costs were obtained by multiplying unit cost by the 
resource use. 
Consequences
The type of complications (cardiac, renal, pulmonary, 
and neurological) included in this analysis corresponds to 
the model developed by Hayes et al.20 The probability of 
occurrence of events, including death, are also those used 
by Hayes et al.,20 obtained from randomized clinical trials. 
Sensitivity analysis
Utilities used in the model are shown in Table 2. A one-way 
deterministic sensitivity analysis was performed to explore 
Table 2 Utilities for EVAR and OR in the À rst year and annually thereafter.
EVAR OR
 First 
year
Annually 
thereafter
Reference First 
year
Annually 
thereafter
Reference
Intervention 0.740 0.745 EVAR 1 Trial 0.750 0.745 EVAR 1 Trial
Complications
Cardiac 0.683 0.718 Jones et al., 2004 0.683 0.718 Jones et al., 2004
Renal failure
 Permanent 0.44 0.44 Lee et al., 2005 0.44 0.44 Lee et al., 2005 / 
Mowatt et al., 2003
 Temporary 0.44 1.00 Assumption 0.44 1.00 Assumption
Pulmonary 0.884 1.00 CEA registrya 0.884 1.00 CEA registry
Neurologic Stroke
 Disabling 0.38 0.38 Jones et al., 2004 0.38 0.38 Jones et al., 2004
 Non-disabling 0.74 0.74 Jones et al., 2004 0.74 0.74 Jones et al., 2004
a Cost-effectiveness analysis registry.
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the impact of uncertainties in the model inputs on the 
cost-effectiveness. For consequences we used as lower 
and upper values the 95% confidence interval bounds from 
clinical studies. For costs we assumed 50% up and down 
variations for all inputs. This assumption is above the usual 
practice (30%), but we considered it to be more appropriate 
to test the robustness of our findings, given that our cost 
data were collected through expert panel survey instead of 
observational studies.
Table 3 shows the comparison of total costs of primary 
intervention, complications, and re-interventions of EVAR 
and OR. In the primary intervention we included all relevant 
cost items such as staff time, blood products, number of 
days in ICU, LOS, drugs, and diagnostic tests. 
The major cost difference in the primary intervention 
(difference of 3,064€ in favor of OR) is related to the 
cost of the endograft/graft (8,027 € versus 968 €). For 
the complications and re-interventions, differences are 
negligible. 
Main results from the cost-effectiveness analysis are 
in Table 4. Over a 30-year time horizon patients treated 
with EVAR have a mean undiscounted life expectancy 
of 10,260 years, and 10,087 years for those treated with 
OR. Treatment with EVAR thus results in incremental 
life expectancy of 0,173 life years, which corresponds 
approximately to one and a half months. The mean 
undiscounted quality-adjusted life year expectancy (QALY) 
is 5,709 for EVAR and 5,618 for OR. Discounted values are 
4,226 and 4,156 QALYs, respectively. 
Patients treated with EVAR have 16,709€ mean cost, and 
12,130€ for OR patients, resulting in an incremental cost of 
4,578€. The incremental cost-effectiveness ratio is 33,918€ 
per life year gained and 65,605€ per QALY gained, using 
discounted cost and consequences.
Results from the deterministic sensitivity analysis are 
presented in Table 5. We show data only for the conse-
quences and costs that most alter the incre mental cost-
effectiveness ratio. EVAR is dominated when short and 
long-term mortality risk ratios are less favorable. In the 
contrary case, the ICER falls well below 50,000€/QALY, 
Table 3 Cost of primary intervention, complications 
and reinterventions for EVAR and OR.
Primary intervention EVAR 
(€)
OR 
(€)
DIFF 
(EVAR-OR) 
(€)
Total 11,461 8,397 3,064
Complications and 
 re-interventions
Complications – 30 days
 Cardiac (MI) 70 167 î97
 Renal failure 23 39 î16
 Pulmonary 0 0 0
 Neurologic (stroke) 11 32 î21
Complications — 1-18 months
 Cardiac (MI) 11 3 8
 Renal failure 0 0 0
 Pulmonary 0 0 0
 Neurologic (stroke) 4 2 1
Reinterventions — 30 days 82 49 33
Reinterventions — 2-6 months 82 49 33
Reinterventions — Long term 13 — —
Table 4 Results from cost-effectiveness analysis — Base 
case.
EVAR OR Incremental 
(€)
Discounted average cost, € 16,709 12,130 4,578
Undiscounted life years 10,260 10,087 0,173
Undiscounted QALYs 5,709 5,618 0,091
Discounted QALYs 4,226 4,156 0,070
Cost per LY gained, € 33,918
Cost per QALY gained, € 65,605   
Table 5 Results from one-way deterministic sensitivity analysis.
Base case
Inputs ICER (€/QALY)
 value Low estimate High estimate At low estimate At high estimate
Base case: 65,605 €/QALY
Consequences (using 95% CI)
 EVAR RR 30-day mortality 0.380 0.180 0.800 43,332 Dominated
 EVAR RR long-term all-cause mortality 1.055 0.844 1.266 21,040 Dominated
 OR 30-days mortality 0.042 0.026 0.058 176,641 40,249
 OR long-term all-cause mortality 0.005 0.000 0.010 37,272 198,455
 OR RR short term neurological compl. 2.830 0.980 8.160 92,858 32,267
Costs (using 50% variation)
 Device cost OR 968 484 1,452 72,539 58,669
 EVAR intensive care unit 702 351 1,053 60,588 70,627
 OR intensive care unit 3,532 1,766 5,298 90,916 40,310
 EVAR post-operative ward 1,741 870 2,611 53,153 78,049
 OR post-operative ward 2,452 1,226 3,678 83,165 48,033
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and even below 30,000€/QALY in the favorable long-term 
mortality scenario. 
The ICER also becomes more favorable to EVAR when we 
artificially increase the costs of OR stays in intensive care 
and post-operative units, although values remain above 
30,000€/QALY. The impact of changing the discount factor 
and mean age at intervention is marginal.
Finally, replacing outcomes from clinical trials with 
those mentioned by the expert panel survey does not 
alter results significantly, as the cost-effectiveness 
ratio rises to 58,669€/QALY (Table 6). Results improve 
dramatically if we consider only the panel’s outcome 
for 30-day mortality (21,458 €/QALY) but worsen if we 
consider the panel’s outcomes for long-term mortality 
(67,577 €/QALY). The difference in the relative risk of 
30-day mortality (0,128 versus 0,380) certainly explains 
the first result, combined with the lower mortality from 
OR (6.8% versus 4.2%) and lower mortality from EVAR 
(0.9% versus 1.7%). 
Discussion
There is a consensus that EVAR significantly reduces 
short-term mortality, resulting in an early survival advantage. 
Also, EVAR is a less invasive procedure as compared 
to conventional OR, leading to fewer post-operative 
complications, faster recovery, and shorter hospital stays. 
An unquestionable advantage of the EVAR is also in 
the treatment of certain sub-groups of patients who 
previously had no treatment option, with consequent 
health gains.28 However, some concerns remain regarding 
the long-term results of EVAR, namely its increased need 
for re-interventions and its benefits on long-term survival 
In addition, the incremental cost of EVAR raises questions 
about the economic value of this intervention.16,29-31
This study examines the cost-effectiveness of EVAR as 
compared to OR to treat abdominal aortic aneurysm from 
the NHS perspective. 
In general, findings are in line with earlier literature 
showing that EVAR represents additional costs as compared 
to OR, but provides additional benefits in life expectancy 
and quality of life.2,7,11,29 These benefits are concentrated in 
the short/mid-term (up to 2 years) period after intervention. 
Based on this study, the value of EVAR is of 65,605€/QALY, 
which is above the commonly accepted cost-effectiveness 
threshold in Portugal (although no official threshold exists, 
“informal” evidence suggests a value of 30,000€/QALY). 
However, this value gets close to 30,000€/QALY when we 
assume that EVAR benefits are extended to the long term. 
In this sense, Quinney et al.,10 and Jackson et al.14 recently 
found a survival advantage of EVAR after 100 months and 
at five years of follow-up, respectively. These new findings 
suggest an improved benefit of endovascular repair over 
time.
Finally, the cost-effectiveness ratio is not altered as we 
replace outcomes mentioned in clinical trials with those 
mentioned by our panel of Portuguese specialists (58,669 €/
QALY). However, outcomes become highly favorable to EVAR 
as we consider the panel’s outcome for 30-day mortality 
(21,458 €/QALY). This result must be interpreted with 
caution. On the one hand, a survey of a restricted number 
of experts is certainly not as reliable as outcomes from 
randomized clinical trials.32 On the other hand, clinical 
trials are performed in a very specific context that may 
not apply in real conditions, subject to differences in 
practices, adherence to treatment or budget constraints, 
among others.32 We also cannot ignore the possibility 
that Portuguese practices produce different clinical 
outcomes compared to those obtained in other countries. 
To conclude, although clinical outcomes in Portugal would 
require validation using more accurate data (for instance, 
from observational studies; RCTs, and National Registries), 
cost-effectiveness ratios based on available clinical 
information for Portugal are quite favorable, and confirm 
the promising value of EVAR.
This study suffers from the usual limitations of model-
based economic evaluations, namely the impos sibility to 
observe long-term effects, which are instead estimated 
based on available data and assumptions. This is inevitable 
as we seek to support decisions in the short term based 
on available information. Also, clinical effects in the 
base model are based on data from the literature and 
not on observational data for Portugal. However, these 
data are based on large clinical trials whose results have 
been published in reputable international scientific 
journals, and we have no reason to believe the impact of 
interventions would differ in Portugal as compared to other 
Table 6 Results using consequences obtained from the expert panel survey.
 ICER (€/QALY)
30-day mortality only
 RR EVAR versus OR: 0.128 (versus 0,380 in the base case) 21,458
 OR mortality: 0,068 (versus 0,042 in the base case)
 EVAR mortality: 0,009 (versus 0,016 in the base case)
Long-term all-cause mortality only
 RR EVAR versus OR: 0,848 (versus 1,055 in the base case) 67,577
 OR mortality: 0,200 (versus 0,005 in the base case)
 EVAR mortality: 0,175 (versus 0,005 in the base case)
30-day mortality and long-term mortality (RR EVAR versus OR) 58,669
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industrialized countries. Third, cost data were obtained 
from an expert panel survey, which is certainly less 
reliable than systematic observational data based e.g. on 
clinical records. However, this technique is widely used in 
economic evaluation, and our results are found to be highly 
robust to large changes (50%) in cost values. Moreover, 
the modified Delphi technique is commonly performed 
and accepted in the economic evaluation literature,33 in 
the definition of therapeutic guidelines,34 and to measure 
clinical practice.35
Finally, we were not able to distinguish different 
population sub-groups. The York Report of economic 
evaluation (2009) considers that EVAR is likely to be 
cost-effective in patients with high operative risk and in 
patients with small aneurysms. It is also considered that 
the cost-effectiveness of EVAR may be sensitive to the 
patient s´ age and fitness at intervention.36 The recent 
NICE technology appraisal guidance (2009) reviewed in 
2012, considers that EVAR is likely to be cost-effective for 
patients of moderate fitness and with large aneurysms 
(>7.5 cm) aged 80 years and older, and for patients with poor 
fitness, aged 75 years and older with aneurysm size between 
5.5 cm and 6.0 cm.37 Further research using Portuguese data 
should consider these aspects.
Finally, Portuguese data from all NHS hospitals indicate 
that patients treated with OR are more likely to be 
admitted to nursing homes than patients treated with 
EVAR (5.6% versus 10.8%), confirming recent results from 
the literature.19,38 The consequences of this difference 
were not included in our study as no reliable data were 
available about the additional cost of these stays at nursing 
homes, leading to an underestimation of the value of 
EVAR. Indeed, this would require estimating their length 
and daily price, which is not a trivial issue as those services 
are mostly provided privately in Portugal (there are no 
official fees and prices differ across patients and facilities). 
More generally, we could not account in our study for the 
out-of-hospital costs borne by the patient and the State, 
which include nursing homes and primary care, drugs 
bought at community pharmacies, social services, and 
family support. 
Conclusion
The highly indebted of the Portuguese National Health 
Service emphasizes the need to guarantee universal 
coverage and high quality of care at a sustainable cost. 
Economic evaluations of health care interventions 
represent a valuable instrument to help decision-makers 
adopt the strategies that bring greater benefits at lower 
costs - value for money. One of the main points that come 
up indirectly from this study is that we need more robust 
data for Portugal, mainly from observational studies, 
clinical registries and about costs. Endovascular repair 
of aortic abdominal aneurysm seems to represent an 
effective alternative and has been used increasingly in 
Portugal and elsewhere. Our study shows that its cost-
effectiveness is currently above the commonly accepted 
threshold in Portugal, but that the economic value of EVAR 
would greatly improve if benefits were confirmed in the 
long run following the intervention.
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